Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Gwo-Shu Mary Lee.
Connection Strength

3.192
  1. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clin Cancer Res. 2021 04 01; 27(7):2087-2099.
    View in: PubMed
    Score: 0.229
  2. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80.
    View in: PubMed
    Score: 0.194
  3. Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis. 2018 Mar 13; 7(3):30.
    View in: PubMed
    Score: 0.188
  4. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
    View in: PubMed
    Score: 0.180
  5. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):726-734.
    View in: PubMed
    Score: 0.168
  6. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate. 2016 May; 76(7):691-9.
    View in: PubMed
    Score: 0.162
  7. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2016 Feb 01; 34(4):352-9.
    View in: PubMed
    Score: 0.161
  8. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
    View in: PubMed
    Score: 0.156
  9. The role of miRNAs in prostate cancer. Eur Urol. 2015 Oct; 68(4):589-90.
    View in: PubMed
    Score: 0.151
  10. Emerging players in prostate cancer: long non-coding RNAs. Am J Clin Exp Urol. 2014; 2(4):294-9.
    View in: PubMed
    Score: 0.150
  11. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24.
    View in: PubMed
    Score: 0.144
  12. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2013 Mar; 73(4):346-54.
    View in: PubMed
    Score: 0.128
  13. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 01; 72(10):1093-103.
    View in: PubMed
    Score: 0.122
  14. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50.
    View in: PubMed
    Score: 0.120
  15. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
    View in: PubMed
    Score: 0.117
  16. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51.
    View in: PubMed
    Score: 0.112
  17. Role of microRNA-221/-222 in cancer development and progression. Cell Cycle. 2009 Aug; 8(15):2315-6.
    View in: PubMed
    Score: 0.104
  18. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009 Apr 15; 69(8):3356-63.
    View in: PubMed
    Score: 0.101
  19. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008 Jun 01; 68(8):839-48.
    View in: PubMed
    Score: 0.095
  20. A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate. 2016 10; 76(14):1338-41.
    View in: PubMed
    Score: 0.042
  21. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016 May 31; 113(22):6259-64.
    View in: PubMed
    Score: 0.041
  22. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1050-1058.
    View in: PubMed
    Score: 0.041
  23. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. Clin Cancer Res. 2015 Dec 15; 21(24):5578-87.
    View in: PubMed
    Score: 0.039
  24. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
    View in: PubMed
    Score: 0.036
  25. Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
    View in: PubMed
    Score: 0.035
  26. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.033
  27. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012 Nov; 13(11):1105-13.
    View in: PubMed
    Score: 0.032
  28. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int. 2011 Oct; 108(7):1086-91.
    View in: PubMed
    Score: 0.029
  29. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28.
    View in: PubMed
    Score: 0.029
  30. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8.
    View in: PubMed
    Score: 0.028
  31. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.